Photo: Prensa Latina

Havana, Sep 3 (RHC) -- A total of 14,115,595 doses of nationally produced anti-Covid-19 vaccines have already been administered in Cuba, the Ministry of Public Health (MINSAP) informed on Thursday.

According to the latest report posted on MINSAP's website, 5,5 million people have received at least a first dose of one of the country's vaccines, representing 49.7 percent of the national population.

Just a few days ago, the medicine regulatory entity authorized Abdala (CIGB-66), Soberana 02, and Soberana Plus, already as vaccines, for massive emergency use, allowing Cuba to become the first country in Latin America to develop this kind of drug.

Abdala, designed by the Genetic Engineering and Biotechnology Center (CIGB), has a three-dose scheme with a time gap of 14 days between each. In Phase III trials, it proved to have 92.28-percent efficacy and 100 percent against severe disease and death.

Soberana 02, developed by the Finlay Vaccine Institute (IFV) along with Soberana Plus, showed 91.2 percent efficacy in Phase III trials.